MedTrace Logo

Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration

NCT02302989 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2018-08-28

No results posted yet for this study

Summary

To evaluate Ranibizumab as prophylaxis against the conversion to neovascular Age-Related Macular Degeneration

Conditions

  • Age-related Macular Degeneration

Interventions

DRUG

Ranibizumab 0.5mg

Sponsors & Collaborators

  • NJ Retina (Retina Associates of New Jersey)

    collaborator OTHER

  • Leonard Feiner, MD, PhD

    lead OTHER

Principal Investigators

  • Leonard Feiner, MD, MD, PhD · NJ Retina (Retina Associates of New Jersey)

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2018-07-31
Completion
2018-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02302989 on ClinicalTrials.gov